Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Newman Yeilding"'
Autor:
Carrie Brodmerkel, Cynthia Guzzo, Jacqueline Benson, Jill Giles-Komar, Newman Yeilding, Mary Ann Mascelli, Brad Schenkel, Michael Plotnick, Kavitha Goyal, Honghui Zhou, Philippe Szapary
Publikováno v:
Annals of the New York Academy of Sciences. 1263:1-12
Autor:
Kristian Reich, Nehal N. Mehta, Richard G. Langley, Daniel J. Rader, Philippe Szapary, Ulrich Mrowietz, Newman Yeilding, Ming-Chun Hsu, Alexa B. Kimball, Yin You
Publikováno v:
Journal of the American Academy of Dermatology. 67:76-85
Background Patients with psoriasis are known to have an increased number of cardiovascular (CV) risk factors and be at increased risk for CV events. Objectives We sought to describe and characterize the underdiagnosis and undertreatment of CV risk fa
Autor:
Shu Li, Brad Schenkel, Steven Fakharzadeh, Kenneth B. Gordon, Kim A. Papp, Newman Yeilding, Alexa B. Kimball, Philippe Szapary, Cynthia Guzzo
Publikováno v:
British Journal of Dermatology. 166:861-872
Summary Background An unmet need remains for safe and effective long-term treatments of psoriasis. Objectives To evaluate ustekinumab efficacy and safety for up to 3 years in the PHOENIX 1 trial. Methods Patients (n = 766) with moderate-to-severe pso
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 38:497-517
Disease status is often measured with bounded outcome scores (BOS) which report a discrete set of values on a finite range. The distribution of BOS data is often non-standard, e.g., J- or U-shaped, thus making standard analysis methods that assume no
Autor:
Richard G. Langley, Newman Yeilding, Yaowei Zhu, Kim A. Papp, Y. Wang, Philippe Szapary, Shu Li, Kristian Reich, Mark Lebwohl
Publikováno v:
Journal of the American Academy of Dermatology. 63:571-579
Background Patients with psoriasis tend to be overweight, and the efficacy of fixed-dose biologics may be compromised by high body weight. Objective We sought to determine whether the optimal dose of ustekinumab is affected by weight in patients with
Positive treatment effects of ustekinumab in psoriasis: Analysis of lesional and systemic parameters
Autor:
Newman Yeilding, Manjula Reddy, Charles Pendley, Thomas S. McCormick, Kevin D. Cooper, Stephen Xu, Carrie Brodmerkel, Y. Wang, Gisela Torres, Colleen Marano, Jackson Wong, Uma Prabhakar, Cuc Davis
Publikováno v:
The Journal of Dermatology. 37:413-425
Ustekinumab, a human anti-interleukin (IL)-12/IL-23p40 monoclonal antibody has demonstrated significant efficacy in patients with moderate-to-severe psoriasis. Skin lesion biopsies, cell surface markers on peripheral blood lymphocytes, and ex vivo T-
Autor:
Mark Lebwohl, Kim A. Papp, Newman Yeilding, Y. Wang, B. Schenkel, Gerald G. Krueger, Chenglong Han
Publikováno v:
British Journal of Dermatology. 162:137-146
Background PHOENIX 1 was a phase III, randomized, double-blind, placebo-controlled study that demonstrated the long-term efficacy and safety of ustekinumab in patients with moderate-to-severe psoriasis. Objectives To assess the effect of ustekinumab
Autor:
Kim A Papp, Richard G Langley, Mark Lebwohl, Gerald G Krueger, Philippe Szapary, Newman Yeilding, Cynthia Guzzo, Ming-Chun Hsu, Yuhua Wang, Shu Li, Lisa T Dooley, Kristian Reich
Publikováno v:
The Lancet. 371:1675-1684
Autor:
Craig L, Leonardi, Alexa B, Kimball, Kim A, Papp, Newman, Yeilding, Cynthia, Guzzo, Yuhua, Wang, Shu, Li, Lisa T, Dooley, Kenneth B, Gordon, P, Ghislain
Publikováno v:
The Lancet. 371:1665-1674
Interleukins 12 and 23 have important roles in the pathophysiology of psoriasis. We assessed ustekinumab, a human monoclonal antibody directed against these cytokines, for the treatment of psoriasis.In this phase III, parallel, double-blind, placebo-
Autor:
Alexa B. Kimball, Y. Wu, K. Fraeman, Don Robinson, Mohan Bala, C. Paramore, Cynthia Guzzo, Newman Yeilding
Publikováno v:
Dermatology. 217:27-37
Background: Cardiovascular diseases or risk factors (CVDR) seem to be more common in psoriasis patients than in the general population. Objective: We assessed the relationship of psoriasis with CVDR by analysis of healthcare claims data using a cross